Oric Pharmaceuticals, Inc. financial data

Symbol
ORIC on Nasdaq
Industry
Pharmaceutical Preparations
Location
240 E. Grand Ave., 2 Nd Floor, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.45K % +2.4%
Debt-to-equity 9.27 % -11.6%
Return On Equity -42.5 % -7.22%
Return On Assets -38.9 % -8.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 70.6M shares +29.4%
Common Stock, Shares, Outstanding 70.6M shares +29.4%
Entity Public Float 415M USD +140%
Common Stock, Value, Issued 7K USD +16.7%
Weighted Average Number of Shares Outstanding, Basic 70.5M shares +22.9%
Weighted Average Number of Shares Outstanding, Diluted 70.5M shares +22.9%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 28.2M USD +15.1%
Operating Income (Loss) -135M USD -32.8%
Nonoperating Income (Expense) 14.9M USD +80.2%
Net Income (Loss) Attributable to Parent -120M USD -28.6%
Earnings Per Share, Basic -1.8 USD/shares +9.55%
Earnings Per Share, Diluted -1.8 USD/shares +9.55%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 44.2M USD +68.6%
Assets, Current 279M USD +20.3%
Property, Plant and Equipment, Net 3.09M USD +0.95%
Operating Lease, Right-of-Use Asset 9.14M USD -16.8%
Other Assets, Noncurrent 9.55M USD -6.07%
Assets 302M USD +10.1%
Accounts Payable, Current 4.25M USD +13.7%
Accrued Liabilities, Current 17M USD +11.8%
Liabilities, Current 21.2M USD +12.2%
Operating Lease, Liability, Noncurrent 7.46M USD -21%
Other Liabilities, Noncurrent 6.83M USD -14.4%
Liabilities 28.1M USD +4.29%
Accumulated Other Comprehensive Income (Loss), Net of Tax 722K USD
Retained Earnings (Accumulated Deficit) -526M USD -29.5%
Stockholders' Equity Attributable to Parent 274M USD +10.7%
Liabilities and Equity 302M USD +10.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -30.2M USD -46.3%
Net Cash Provided by (Used in) Financing Activities 125M USD
Net Cash Provided by (Used in) Investing Activities -61.9M USD -584%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 70.6M shares +29.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 33M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 44.7M USD +67.3%
Deferred Tax Assets, Valuation Allowance 133M USD +31.1%
Deferred Tax Assets, Gross 136M USD +29.6%
Operating Lease, Liability 10.2M USD -15.6%
Depreciation 261K USD +3.16%
Payments to Acquire Property, Plant, and Equipment 218K USD -29.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -119M USD -29.3%
Lessee, Operating Lease, Liability, to be Paid 12M USD -18.7%
Property, Plant and Equipment, Gross 10.3M USD +7.05%
Operating Lease, Liability, Current 3.12M USD +14.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.68M USD -6.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.85M USD +3.48%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.81M USD -32.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.68M USD +0.04%
Deferred Tax Assets, Operating Loss Carryforwards 75.8M USD +18.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200M shares 0%
Unrecognized Tax Benefits 2.81M USD +29.4%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.77M USD +3.51%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 2.68M USD -15.8%
Share-based Payment Arrangement, Expense 18.9M USD +31.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%